Y'all straight up dumbasses. You see the data BI drug vs. Intermune? Its a dam tie. Neither has advantage. BI has mortality data. Not significant. Intermune had to pool a bunch of other studies to get the mortality data it is not "clean". FDA may not let Inter use mortality data anyhow.
If you pool the data of BI's drug like IM did, than on a pure head to head basis, Nintedanib FVC decline was 54% vs. placebo, that is superor to Pirfenidone
Good luck selling this 50/50 drug. Don't let management tell you anything different. It's a coin flip. Sales are gonna suck post launch 6 mos. They will be flat. Stock will go down.
You better get RSU's, fuck them options. You will not make money on options. You heard it here 1st.
